---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044096"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:47:37.728836+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axsome solriamfetol Phase 3 ADHD trial meets primary endpoint (p=0.039)

## Summary
- AISRS total score reduced 17.7 pts vs 14.3 for placebo at Week 6 (p=0.039) with 150 mg dose.
- Key secondary endpoint CGI-S severity score also significant (p=0.017) for 150 mg solriamfetol.
- 53.5% of 150 mg patients achieved clinical response (≥30% AISRS reduction) vs 41.3% placebo (p=0.024).
- Onset of improvement observed as early as Week 1 (p=0.036) vs placebo.
- Company plans to initiate pediatric ADHD trial in 2025; safety profile consistent with prior studies.

## SEC filing metadata
- accession: 0000950170-25-044096
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025044096/0000950170-25-044096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025044096/axsm-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044096
- JSON: https://secwatch.observer/filing/0000950170-25-044096.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.